7759.TWO SUNHAWK BIO

Healthcare Biotechnology Taiwan OTC Exchange
49.95 TWD
Close of Nov 6, 2026
25.60 70.10
Market cap
TWD 3.51B
P/E
-
P/B
9.21x
ROE
-36.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 7759.TWO undervalued?

Graham number

The Graham number of SUNHAWK BIO cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SUNHAWK BIO fundamental analysis

No fundamental analysis for SUNHAWK BIO yet.

SUNHAWK BIO stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SUNHAWK BIO

Sunhawk Vision Biotech, Inc., a drug development company, engages in the research and development of children's myopia eye drops, dry eye drops, and other nucleic acid new drugs for the treatment of ocular surface diseases in Taiwan. The company develops SHJ002 eye drops, which have completed a Phase 2 clinical trial for the treatment of dry eye disease in adult patients and corneal erosion in patients with Sjogren's syndrome, as well as in a Phase 2 clinical trial for myopi…

Full company profile